Board of Directors
Edward Mathers, Chairman
New Enterprise Associates
Edward Mathers has served on the Ra Pharma® Board of Directors since 2010. Since August 2008, Mr. Mathers has been a Partner at New Enterprise Associates, Inc., or NEA, a private venture capital firm focusing on technology and healthcare investments. Mr. Mathers is a director of Liquidia Technologies, Inc., Rhythm Pharmaceuticals, Inc., Envisia Therapeutics, Inc., Synlogic, Inc., Mirna Therapeutics, Inc., Lumos Pharma, Inc., Ziarco, Inc., Amplyx Pharmaceuticals, Inc. and ObsEva SA. He is also a member of NC State’s College of Sciences Foundation board. Mr. Mathers earned his B.S. in Chemistry from North Carolina State University.
Peter Tuxen Bisgaard
NF Life Sciences
Peter Tuxen Bisgaard has served as a member of the Ra Pharma Board of Directors since 2015. Mr. Bisgaard is currently the Managing Director of NF Life Sciences, which is a large global investor in health care and life sciences companies. Previously, Mr. Bisgaard was employed as a Senior Partner at Novo Ventures (US) Inc., which provides consultancy services to Novo A/S, a Danish limited liability company that manages investments and financial assets. He is and has been a member of the Board of Directors of a number of private and public biotech and medtech companies including Nevro Corp, Alder Biotherapeutics, Otonomy, HTG Molecular Diagnostics, Entasis Therapeutics, Outpost Medicine, Bolt Therapeutics and Inozyme. Mr. Bisgaard obtained an M.Sc. in 1998 from the Technical University of Denmark and was at the same time awarded a post graduate degree in Mathematical Modeling in Economics by the European Consortium for Mathematics in the Industry.
Robert Heft, Ph.D.
Robert Heft, Ph.D., has served on the Ra Pharma Board of Directors since March 2016. Dr. Heft currently serves as Chief Executive Officer of Zingenix Ltd., a company focused on gene therapy for severe orphan disorders. Prior to Zingenix, Dr. Heft was Chief Executive Officer and member of the Board of Directors of Enobia Pharma Inc. from 2005 to 2012. Dr. Heft currently serves on the boards of Zingenix Ltd., VisionGate, Inc., Lumos Pharma, Inc., and Clementia Pharmaceuticals, Inc. He also serves on the Advisory Board of Sectoral Asset Management. Dr. Heft received a Bachelor of Engineering Degree from McGill University, a Master of Engineering Degree from Cornell University and a Ph.D. from the Massachusetts Institute of Technology in Genetic Engineering and Radiological Sciences.
Timothy Pearson has served as a member of Ra Pharma’s Board of Directors since May 2016. Mr. Pearson currently serves as Chief Financial Officer of TESARO, Inc., an oncology-focused biopharmaceutical company, where he has served since May 2014. Prior to joining TESARO, from August 2011 to July 2012, Mr. Pearson served as an Executive Vice President and the Chief Financial Officer of Catalyst Health Solutions, Inc. where he led the finance and strategic planning functions. Mr. Pearson holds a B.S. in Business Administration from the University of Delaware, an M.S. in Finance from Loyola College and a B.S. in Accounting from the University of Maryland University College. He is also a Certified Public Accountant.
RA Capital Management
Rajeev Shah has served as a member of the board of directors of Ra Pharma since July 2015. Mr. Shah is a Partner and Portfolio Manager at RA Capital Management, LLC, an investment advisory firm that has been investing in health care companies since 2002. Mr. Shah received a B.A. in Chemistry from Cornell University.
Aoife M. Brennan, M.B., B.Ch.
Aoife M. Brennan, M.B., B.Ch., has served on the Ra Pharma Board of Directors since September 2018. Dr. Brennan currently serves as Interim President and Chief Executive Officer and Chief Medical Officer of Synlogic, Inc., a company focused on developing innovative products based on the tools and principles of synthetic biology to genetically re-program beneficial bacteria. Dr. Brennan joined Synlogic in 2016 from Biogen, where she most recently served as Vice President and Head of the Rare Disease Innovation Unit, which included programs ranging from pre-clinical to commercial. Dr. Brennan also led programs across multiple therapeutic areas including the late phase development of nusinersen for spinal muscular atrophy and ALPROLIX™ and ELOCTATE™, treatments for Hemophilia B and Hemophilia A. Prior to joining Biogen, she was director of clinical development at Tolerx, a biotechnology company focusing on immunotherapy for Type 1 diabetes. Dr. Brennan holds a medical degree from Trinity College in Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology, and metabolism. Prior to joining the biotechnology industry, she was a Clinical Research Fellow in the Division of Endocrinology, Diabetes, and Metabolism at Beth Israel Deaconess Medical Center and the Joslin Diabetes Center in Boston, and a Scholar in Clinical Science at Harvard Medical School.
Douglas Treco, Ph.D.
Doug Treco has been Chief Executive Officer of Ra Pharma since he co-founded the Company in June 2008, and serves on the Company’s Board of Directors. Dr. Treco was an Entrepreneur-in-Residence at Morgenthaler Ventures from January 2008 to May 2014. In 1988, he co-founded Transkaryotic Therapies Inc., or TKT, a multi-platform biopharmaceutical company developing protein and gene therapy products, which was acquired by Shire Pharmaceuticals Group plc. Dr. Treco was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School from 2004 to 2007. Dr. Treco received his Ph.D. in Biochemistry and Molecular Biology from the State University of New York, Stony Brook, and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital.